Barclays’s Juno Therapeutics, Inc. JUNO Stock Holding History

Barclays’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-124,704	Closed	-$5.7M	–	7594
2017 Q4	$5.7M	Sell	124,704 -112,383	-47%	-$5.61M	﹤0.01%	1572
2017 Q3	$10.6M	Buy	237,087 +212,474	+863%	+$7.24M	0.01%	1016
2017 Q2	$736K	Buy	24,613 +20,911	+565%	+$516K	﹤0.01%	3153
2017 Q1	$82K	Sell	3,702 -19,087	-84%	-$409K	﹤0.01%	5035
2016 Q4	$429K	Buy	22,789 +17,743	+352%	+$434K	﹤0.01%	3507
2016 Q3	$151K	Sell	5,046 -20,301	-80%	-$632K	﹤0.01%	4197
2016 Q2	$975K	Sell	25,347 -37,092	-59%	-$1.54M	﹤0.01%	2634
2016 Q1	$2.37M	Buy	62,439 +59,349	+1,921%	+$2.07M	﹤0.01%	1767
2015 Q4	$134K	Buy	3,090 +1,097	+55%	+$54.4K	﹤0.01%	4224
2015 Q3	$80K	Sell	1,993 -6,511	-77%	-$286K	﹤0.01%	4757
2015 Q2	$450K	Buy	8,504 +8,296	+3,988%	+$440K	﹤0.01%	3558
2015 Q1	$13K	Buy	+208	New	+$10.1K	﹤0.01%	6095

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Barclays's JUNO Position: Q1 2018 in Review

Barclays sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 124,704 shares — an estimated $5.7M sold.

Barclays first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $10.6M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Barclays reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Barclays sold 124,704 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $5.7M.
Barclays first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
Barclays's Juno Therapeutics, Inc. position peaked at $10.6M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.